Dimitrios L. Wagner
dlwagner.bsky.social
Dimitrios L. Wagner
@dlwagner.bsky.social
Physician & science enthusiast @BCMHouston @ChariteBerlin @BIHregeneration // Genome Editing and Immunology // 50% of @immunoboys.bsky.social / @dlwagnerlabs.bsky.social
Pinned
You like engineering T cells, but you are missing the right flavor?

Check out 'one-pot' PASTA recipe 🔥🍝: www.biorxiv.org/content/10.1101/2025.09.10.675267v1

We combined a unique mix of CRISPR knock-in with serine integrases for easy-to-adopt
𝐏rogrammable
𝐀nd
𝐒ite-specific
𝐓ransgene
𝐀ddition
🧪
Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases
Current gene transfer methods often lack the precision, versatility, or efficiency when integrating large transgenes, limiting the ability to engineer therapeutic T-cells with more complex payloads. H...
www.biorxiv.org
Reposted by Dimitrios L. Wagner
(1/10) How do diverse leukemia mutations converge on the same molecular program? In #RibackLab first manuscript @cp-cell.bsky.social, collaboration with @goodell-lab.bsky.social shows that disparate mutations rewire shared protein networks to form nuclear condensates called C-bodies.
November 4, 2025 at 5:58 PM
Reposted by Dimitrios L. Wagner
Ubiquitinylation is more complex than just a signal for proteasomal degradation: Linear ubiquitinylation of Methionine-1 is important for NFkB signalling.
LOF of the Deubiquitinylase OTULIN leads to an autoinflammatory disease with a TNF positive feedback loop.
🧪 ⑂
1/2
October 20, 2025 at 7:51 PM
Reposted by Dimitrios L. Wagner
Ever noticed that #CRISPR editing results differ between cells? Awesome PhD student Moritz Schlapansky developed "scOUT-seq" to measure single cell transcriptomes + editing. 1.2 million cells, 74 cell types, living 🐭. Cell subtypes differ wildly from bulk average! www.biorxiv.org/content/10.1...
Cell-stereotyped DNA repair outcomes are widespread during genome editing
Genome editing outcomes are governed by DNA repair pathways that vary with cell type and state. We developed scOUT-seq (single-cell Outcomes Using Transcript sequencing), a scalable approach that join...
www.biorxiv.org
October 24, 2025 at 8:44 AM
Reposted by Dimitrios L. Wagner
A new subspecialty takes off! Astroimmunology is focused on the effects of #spaceflight on the #immunesystem and defines avenues for countermeasures. A bonus: the work will also inform research on #aging @natrevimmunol.nature.com evimmunol.nature.com www.buckinstitute.org/news/a-hitch...
A hitchhiker’s guide to the galaxy of space immunology
Buck scientists help define the scope of Astroimmunology   With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years.  Some will even get ...
www.buckinstitute.org
October 16, 2025 at 4:20 PM
Reposted by Dimitrios L. Wagner
BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 (thread 👇)
October 15, 2025 at 12:22 PM
Reposted by Dimitrios L. Wagner
What is a promoter? And how does it work?

We very happy to share our latest work trying to understand enhancer-promoter compatibility.
I am very excited about the results of @blanka-majchrzycka.bsky.social, which changed the way I think about promoters

www.biorxiv.org/content/10.1...
Enhancer-promoter compatibility is mediated by the promoter-proximal region
Gene promoters induce transcription in response to distal enhancers. How enhancers specifically activate their target promoter while bypassing other promoters remains unclear. Here, we find that the p...
www.biorxiv.org
October 16, 2025 at 3:06 PM
Reposted by Dimitrios L. Wagner
Honored to be part of the 2025 #STATWunderkinds! Grateful for the many supportive mentors, colleagues, and friends with special shoutout to @bkleinstiver.bsky.social.

Full list: www.statnews.com/wunderkinds/

@statnews.com @mitdeptofbe.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social
October 15, 2025 at 11:55 AM
“ ‘Off the shelf’ Treg may soon be… on the shelf. “ - awesome quote by Prof. Fadi Issa.

Check out our new story: 👇
www.nature.com/articles/s41...

One week after the Nobel prize for Treg 🍀
October 13, 2025 at 11:09 PM
“Good things take time”

Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function!

A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social
www.nature.com/articles/s41...
October 13, 2025 at 9:30 PM
Reposted by Dimitrios L. Wagner
HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social
www.nature.com/articles/s41...
October 13, 2025 at 5:39 PM
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸

We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸

Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
October 12, 2025 at 1:45 PM
Reposted by Dimitrios L. Wagner
October 11, 2025 at 11:02 AM
Reposted by Dimitrios L. Wagner
TCR activation impairs CAR-T cytotoxicity against separate target cells https://www.biorxiv.org/content/10.1101/2025.10.07.680634v1
October 8, 2025 at 12:15 AM
Reposted by Dimitrios L. Wagner
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
October 5, 2025 at 8:51 PM
Reposted by Dimitrios L. Wagner
Excited to share our preprint📯:
We introduce #IntegrateALL, an open-source RNA-seq pipeline for interpretable molecular diagnostics in acute lymphoblastic leukemia!🧬
Big thanks to Nadine Wolgast & team @ www.uksh.de
, catchall-kfo5010.com!
See: doi.org/p7k5 and 🧵
September 28, 2025 at 8:24 AM
Reposted by Dimitrios L. Wagner
Big shoutout to the whole group who made #IntegrateALL possible - especially @alinamh.bsky.social, Thomas Beder and Claudia Baldus at www.catchall-kfo5010.com
September 28, 2025 at 8:36 AM
Reposted by Dimitrios L. Wagner
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors https://www.biorxiv.org/content/10.1101/2025.09.22.677496v1
September 25, 2025 at 2:16 AM
Reposted by Dimitrios L. Wagner
Check out one of our latest stories about combining our non viral knock-in strategy with integrases for an efficient, targeted integration of transgenes >8kb in human T cells!

‘One-pot’ PASTA: programmable and site specific transgene addition - all in just one reaction 🫕
September 23, 2025 at 4:58 AM
Reposted by Dimitrios L. Wagner
This has been such a great collaboration with @dlwagnerlabs.bsky.social! You really need to check it out

One-pot PASTA 🍝 - a one-step protocol to knock-in large transgenes.
I feel tempted to think about one-pot PIZZA 🍕 next!

First authors Isabell and @therealjonaskath.bsky.social were amazing!!
September 19, 2025 at 3:37 PM
Reposted by Dimitrios L. Wagner
Super-large targeted Knock-Ins in primary T cells, with multigene inserts >8kb, in a single reaction. HOW?? 🙀

Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝

= Programmable And Site-specific Transgene Addition. 😎
September 19, 2025 at 1:33 PM
You like engineering T cells, but you are missing the right flavor?

Check out 'one-pot' PASTA recipe 🔥🍝: www.biorxiv.org/content/10.1101/2025.09.10.675267v1

We combined a unique mix of CRISPR knock-in with serine integrases for easy-to-adopt
𝐏rogrammable
𝐀nd
𝐒ite-specific
𝐓ransgene
𝐀ddition
🧪
Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases
Current gene transfer methods often lack the precision, versatility, or efficiency when integrating large transgenes, limiting the ability to engineer therapeutic T-cells with more complex payloads. H...
www.biorxiv.org
September 19, 2025 at 5:30 AM
🚀 In preparation for releasing two new stories, @therealjonaskath.bsky.social is revisiting the journey so far—sharing the lab’s last six papers.

What a ride it’s been… 🙌🧬🧪🧫
Lab History pt. 1
2022 – 🚨 Our first paper is out! 🚨

virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.

➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation

🧬 A key step toward scalable, non-viral CAR-T cell therapies.

DOI: 10.1016/j.omtm.2022.03.018
September 18, 2025 at 5:05 AM
Reposted by Dimitrios L. Wagner
🚨 Paper alert!
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
Next-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ c...
jitc.bmj.com
September 17, 2025 at 9:44 PM
Reposted by Dimitrios L. Wagner
Plasmacytoid dendritic cells can transition to become cDC2s under to influence of TNF, while type-I interferon reduces TNFR expression and thereby inhibits transition. These transitioned cDC2 seem fully functional. 🧪 ⑂

Hornero et al 2025 in Nat Immunol
www.nature.com/articles/s41...
September 11, 2025 at 2:51 AM
Reposted by Dimitrios L. Wagner
23 tools to work with (single-cell) TCR/BCR-seq immune repertoire data 🧵 👇
September 8, 2025 at 2:15 PM